Brixadi, an Extended-Release Injection, Receives FDA Approval for Treating Opioid Use Disorder – Drugs.com MedNews
The opioid epidemic has been a major public health crisis in the United States for several years. According to the National Institute on Drug Abuse, more than 130 people die every day from opioid overdose. In response to this crisis, the FDA has approved a new medication called Brixadi for the treatment of opioid use disorder.
Brixadi is an extended-release injection that contains buprenorphine, a medication that is used to treat opioid addiction. Buprenorphine is a partial opioid agonist, which means that it activates the same receptors in the brain as opioids but produces a weaker effect. This helps to reduce cravings and withdrawal symptoms without producing the same level of euphoria as opioids.
Brixadi is administered once a month by a healthcare provider. This makes it a convenient option for people who have difficulty adhering to a daily medication regimen. It also eliminates the need for daily visits to a clinic for medication-assisted treatment.
The approval of Brixadi is significant because it provides another option for people who are struggling with opioid addiction. Currently, the most commonly used medications for opioid addiction are methadone and buprenorphine/naloxone (Suboxone). While these medications have been effective in reducing opioid use and improving outcomes for people with opioid addiction, they are not suitable for everyone.
Methadone can only be dispensed through specialized clinics, which can be difficult for some people to access. Suboxone can be prescribed by any healthcare provider who has completed the necessary training, but it can be expensive and may not be covered by insurance.
Brixadi offers an alternative that may be more accessible and affordable for some people. It also has the potential to improve adherence to medication-assisted treatment, which is critical for successful outcomes.
However, it is important to note that Brixadi is not a cure for opioid addiction. It is one component of a comprehensive treatment plan that should also include counseling and support services. It is also important to follow the instructions for use carefully and to report any side effects or concerns to a healthcare provider.
In conclusion, the approval of Brixadi is a positive development in the fight against the opioid epidemic. It provides another option for people who are struggling with opioid addiction and may help to improve outcomes for some individuals. However, it is important to remember that medication-assisted treatment is just one part of a comprehensive approach to treating opioid addiction. Counseling and support services are also critical components of successful treatment.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- Minting the Future w Adryenn Ashley. Access Here.
- Buy and Sell Shares in PRE-IPO Companies with PREIPO®. Access Here.
- PlatoAiStream. Web3 Data Intelligence. Knowledge Amplified. Access Here.
- Source: Plato Data Intelligence.